Sellas Life Sciences Stock Triples After Cancer Vaccine Data
Sellas Life Sciences Group Inc. surged after the drug developer reported positive late-stage trial results for an experimental cancer vaccine to treat an aggressive form of blood cancer.
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.